文献速递细胞病理与分子病理

米兰系统意义不明的异型性(AUS)5年性能数据

The Milan system atypia of undetermined significance: 5-year performance data.
PubMed 文献 · Cancer Cytopathol · 2024-07-14

该研究评估作者机构基于米兰系统报告涎腺细胞病理学中AUS类别的诊断性能,纳入2018至2022年Fimlab实验室所有AUS病例并追踪组织学验证至2023年5月。结果显示AUS占比14.0%,高于参考值,可能受COVID-19疫情影响;恶性风险上下界为21.3%和9.9%,更接近米兰系统第一版参考值。

要点

  • AUS占比14.0%,2020和2021年分别为15%和17.5%,高于参考值。
  • 恶性风险上界21.3%、下界9.9%;肿瘤风险上界69.3%、下界32.1%。
  • AUS诊断至手术切除平均时间6–682天,至重复FNA 10–691天。

核心结论

  • AUS占比高于参考值,可能归因于COVID-19大流行的影响。
  • 本研究计算的恶性风险更接近米兰系统第一版参考值而非第二版。

研究设计与样本

  • 从1157例细针穿刺(FNA)中诊断162例(14.0%)AUS,涉及146例患者,平均年龄66.1±14.9岁。
  • 组织学验证追踪至2023年5月31日,计算恶性风险和肿瘤风险的上下界及时间线。

主要发现

  • 恶性风险上界21.3%、下界9.9%;肿瘤风险上界69.3%、下界32.1%。
  • AUS诊断至手术切除平均时间6–682天,至首次重复FNA 10–691天。
  • AUS百分比在COVID-19大流行年份升高,2020年15%、2021年17.5%。

临床怎么用

  • AUS病例应结合组织学随访和重复FNA进行管理,注意时间间隔可能较长。
  • 在COVID-19大流行期间AUS占比可能升高,判读时应考虑此背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of this study was to evaluate the diagnostic performance of the category atypia of undetermined significance (AUS) at the authors' institution based on the Milan System for Reporting Salivary Gland Cytopathology. METHODS: All AUS cases diagnosed at Fimlab Laboratories between January 1, 2018, and December 31, 2022, were included. Histologic verifications were checked until May 31, 2023. The upper-bound and lower-bound risk of malignancy and risk of neoplasm were calculated. The timelines between the pathology laboratory workflow and patient management were also calculated. RESULTS: From 1157 fine-needle aspirations (FNAs), 162 (14.0%) AUS cases were diagnosed in 146 patients, with an average ± standard deviation age of 66.1 ± 14.9 years. There was variation in the AUS percentages, with higher values during the coronavirus disease 2019 pandemic years (15% and 17.5% in 2020 and 2021, respectively). Seventy-five cases (46.3%) had histologic follow-up: 16 were malignant neoplasms, and 36 were benign neoplasms. The upper and the lower bounds of the-risk of malignancy and risk of neoplasm were 21.3% and 69.3% and 9.9% and 32.1%, respectively. The average time from the first FNA with an AUS diagnosis to surgical resection ranged from 6 to 682 days, and the time to the first repeat FNA ranged from 10 to 691 days. CONCLUSIONS: The results indicated higher percentages of AUS cases compared with the reference value, which may be attributed to the impact of the coronavirus disease 2019 pandemic. The risk of malignancy calculated in this study was closer to the reference value from the first edition of the Milan System for Reporting Salivary Gland Cytopathology compared with the second edition.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Lagerstam H, Tommola E, Kares S, et al. The Milan system atypia of undetermined significance: 5-year performance data. Cancer Cytopathol. 2024. PMID: 39003586. doi:10.1002/cncy.22883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。